News - Page 98 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients

Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients

Post published:August 30, 2022
Post category:Press Release

Read more about the article PsyBio Therapeutics Reports Second Quarter 2022 Financial Results

PsyBio Therapeutics Reports Second Quarter 2022 Financial Results

Post published:August 30, 2022
Post category:Press Release

Read more about the article Wesana Announces Second Quarter 2022 Financial Results

Wesana Announces Second Quarter 2022 Financial Results

Post published:August 30, 2022
Post category:Press Release

Read more about the article Psychedelic Bulletin #116 – Ketamine Combo Co. Scores $10m; DEA Drops Plan to Schedule 2 Psychedelics, for Now; Analysis of Oregon Psilocybin Opt-Outs

Psychedelic Bulletin #116 – Ketamine Combo Co. Scores $10m; DEA Drops Plan to Schedule 2 Psychedelics, for Now; Analysis of Oregon Psilocybin Opt-Outs

Post published:August 29, 2022
Post category:Psychedelic Bulletin

Read more about the article MindMed Completes 1-for-15 Reverse Share Split

MindMed Completes 1-for-15 Reverse Share Split

Post published:August 27, 2022
Post category:Press Release

Read more about the article MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

Post published:August 26, 2022
Post category:Press Release

Read more about the article Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional Mushroom Supplements and Appoints Chief Financial Officer to its Board of Directors

Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional Mushroom Supplements and Appoints Chief Financial Officer to its Board of Directors

Post published:August 25, 2022
Post category:Press Release

Read more about the article MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

Post published:August 25, 2022
Post category:Press Release

Read more about the article FILAMENT HEALTH APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS AND ADVISORY COUNCIL

FILAMENT HEALTH APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS AND ADVISORY COUNCIL

Post published:August 25, 2022
Post category:Press Release

Read more about the article BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects

Post published:August 25, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.